Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 11, 2000

Primary Completion Date

March 27, 2002

Study Completion Date

March 27, 2002

Conditions
Leukemia
Interventions
DRUG

troxacitabine

Trial Locations (20)

10021

Memorial Sloan-Kettering Cancer Center, New York

10595

New York Medical College, Valhalla

12208

Cancer Center of Albany Medical Center, Albany

27710

Duke Comprehensive Cancer Center, Durham

32806

MD Anderson Cancer Center Orlando, Orlando

60611

Northwestern University Medical Center, Chicago

75246

Baylor University Medical Center, Dallas

90048

Cedars-Sinai Comprehensive Cancer Center, Los Angeles

91010-3000

Cancer Center and Beckman Research Institute, City of Hope, Duarte

90033-0804

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

60637-1470

University of Chicago Cancer Research Center, Chicago

21231-2410

Johns Hopkins Oncology Center, Baltimore

19104-4283

University of Pennsylvania Cancer Center, Philadelphia

19107-5541

Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

R3A 1R9

Health Sciences Centre, Winnipeg

K1H 8L6

Ottawa General Hospital, Ottawa

M5G 2M9

Princess Margaret Hospital, Toronto

H1T 2M4

Maisonneuve-Rosemont Hospital, Montreal

H3A 1A1

Royal Victoria Hospital - Montreal, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY